AB-106-G208 (TRUST-II)
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.
State: Active
Recruitment: Closed
NVL-655-01 (ALKOVE-1)
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1).
State: Active
Recruitment: Open
AMBER (4020-01-001)
A Phase 1 dose escalation and cohort expansion study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients with advanced solid tumors.
State: Active
Recruitment: Closed
Combi-TED
A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progressing after first-line chemo-immunotherapy
State: Active
Recruitment: Closed
ARROS-1 (NVL-520-01)
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors
State: Active
Recruitment: Open
TeliMET (M18-868)
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
State: Active
Recruitment: Open
lidERA (GO42784)
A Phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer
State: Active
Recruitment: Closed
REZILIENT2 (TAS6417-201)
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
State: Active
Recruitment: Open
REZILIENT3 (TAS6417-301)
Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
State: Active
Recruitment: Open
BLOOMI (UOMI-002)
Enhancing Quality of Life in Cancer Patients through Tailored Nutrition Support: A Comprehensive Approach
State: Active
Recruitment: Open
EDGE-Lung
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
State: Active
Recruitment: Closed
EUCALYPTUS
A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
State: Active
Recruitment: Open
SMT112-3033 HARMONI-3
A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the first-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
State: Active
Recruitment: Open
LUNAR-2 (EF-44)
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
State: Active
Recruitment: Open
MARIGOLD (20210033)
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
State: Active
Recruitment: Open
FIERCE-HN (AV-299-23-301)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma
State: Active
Recruitment: Open
ARTEMIA (OSE2101C302)
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)
State: Active
Recruitment: Open
SKB264-II-04
A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer
State: Active
Recruitment: Closed
EORTC-2029-LCG
Immunotherapy Consolidation After Radical treatment of Synchronous Oligo-metastatic NSCLC: ICARS
State: Active
Recruitment: Open
LIVIGNO-4 (M23-721)
Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Evaluation of the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy
State: Active
Recruitment: Open
REPOSE MEDOPP662
A phase II study assessing safety and efficacy of Repotrectinib in ROS1-positive non-small cell lung cancer patients with active brain metastasis
State: Active
Recruitment: Open
ALKAZAR (NVL-655-04)
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
State: Active
Recruitment: Open
PONTIAC (MEDOPP556)
A randomized phase II Study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling
State: Active
Recruitment: Open
